Can I survive long term taking Venetoclax?

Venetoclax/Venetoclax (Venetoclax), as a targeted therapy, has shown significant efficacy in clinical trials, especially in the treatment of chronic lymphocytic leukemia (CLL) and related hematological malignancies. However, the question of whether it can achieve long-term survival requires more long-term studies and follow-up data.

Venetoclax/Venetoclax is often used to treat patients with refractory or relapsed CLL, especially when other treatments have failed or are not suitable. Several clinical trials have confirmed the efficacy of venetoclax/venetoclax, including the observation of complete pathological and clinical responses in some cases, implying a significant reduction in patient disease burden.

In a study on venetoclax/venetoclax and antiCD20 antibodies (such as Rituxi mab) combination therapy for CLL, the research results showed that this combination treatment significantly improved the progression-free survival of patients (progression-free survival, PFS). PFS refers to the time during which a patient’s disease does not progress during treatment. Under some experimental conditions, the combination of venetoclax and other drugs not only improved treatment response but also prolonged patients' PFS.

However, the evaluation of long-term survival, especially the long-term follow-up data of patient survival rates, currently requires more time to accumulate and study. Because hematologic malignancies often have a long-term tendency to relapse and progress, assessment of long-term survival with venetoclax/venetoclax will require additional years of follow-up and study.

In addition, the use of venetoclax/venetoclax is also associated with some side effects, including anemia, thrombocytopenia, infection, etc. Therefore, the patient's physical condition needs to be carefully monitored during use and the treatment plan needs to be adjusted as needed. Physicians and patients need to weigh potential benefits and risks while considering long-term survival.

Overall, Venetoclax/Venetoclax’s clinical trial data show its significant effect in the treatment of some hematological malignancies, providing new treatment options for some patients. However, more time and research are needed to answer the question of whether it can achieve long-term survival. As science and technology advance and new clinical studies are conducted, we hope to gain a more complete understanding of the potential impact of venetoclax on long-term patient survival.

Venetoclax/Venetoclax has been launched in China and has been included in medical insurance, and patients can purchase it domestically. Specifications: 100mg*14tablets and the price is around 5,000yuan. Please consult the local hospital pharmacy for specific prices. There are original drugs and generic drugs abroad. The Turkish version of Venetoclax/Venetoclaxoriginal drug on the market overseas, specification: 100mg*112 tablets, costs about 10,000 per box. Foreign generic drugs are relatively cheaper. For example, the generic drugs sold in Laos and Bangladesh are priced at about more than 4,000 yuan for 100mg*120 tablets. The ingredients of original drugs and generic drugs are basically the same.